Tremelimumab is another anti-CTLA-4 mAb in clinical development and trialled in ovarian cancer patients in conjunction with poly (ADP-ribose) polymerase (PARP) inhibitors [175]. The gene discussed is CTLA4; the disease is ovarian carcinoma.